Advancing the battle against acute ischemic syndromes: A focus on the GP IIb-IIIa inhibitors

Pharmacotherapy

Volumn 18, Issue 4, 1998, Pages 663-685

  Dobesh, Paul P ^a   Latham, Keith A ^a  

^a ST LOUIS COLLEGE OF PHARMACY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; EPTIFIBATIDE; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; LAMIFIBAN; TIROFIBAN; UNCLASSIFIED DRUG; XEMILOFIBAN;

ACUTE HEART INFARCTION; ANAPHYLAXIS; BLEEDING; BLOOD TOXICITY; CLINICAL TRIAL; CORONARY ARTERY DILATATION; HUMAN; ISCHEMIA; ORAL DRUG ADMINISTRATION; PATHOGENESIS; RESTENOSIS; REVIEW; STENT; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOGENESIS; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

ACETATES; ACUTE DISEASE; ANTIBODIES, MONOCLONAL; BENZAMIDINES; CLINICAL TRIALS; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; ISCHEMIA; MYOCARDIAL ISCHEMIA; PEPTIDES; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; SYNDROME; TYROSINE;

EID: 0031827114     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (91)

1. Lincoff AM; Topol EJ. Interventional catheterization techniques. In: Braunwald E, ed. Heart disease: a textbook of cardiovascular medicine, 5th ed. Philadelphia: WB Saunders, 1997:1366-91.
2. Ferguson JJ, Wilson JM. Early and late ischemic complications of PTCA. J Invasive Cardiol 1994;6(suppl A):3A-12.
3. Coller BS. The role of platelets in arterial thrombosis and the rationale for blockade of platelet GPIIb-IIIa receptors as antithrombotic therapy. Eur Heart J 1995;16(suppl L):11-15.
4. Frishman WH, Burns B, Atac B, Alturk N, Altajar B, Lerrick K. Novel antiplatelet therapies for treatment of patients with ischemic heart disease: inhibitors of the platelet glycoprotein IIb-IIIa integrin receptor. Am Heart J 1995;130:877-92.
5. Weitz JI, Califf RM, Ginsberg JS, Hirsh J, Theroux P. New antithrombotics. Chest 1995;108(suppl):471S-85.
6. Ferguson JJ. Conventional antithrombotic approaches. Am Heart J 1995;130:651-7.
7. Le Breton H, Plow EF, Topol EJ. Role of platelets in restenosis after percutaneous coronary revascularization. J Am Coll Cardiol 1996;28:1643-51.
8. Coller BS. Platelet GPIIb-IIIa antagonists: the first anti-integrin receptor therapeutics. J Clin Invest 1997;99:1467-71.
9. Nurden AT. Polymorphisms of human platelet membrane glycoproteins: structure and clinical significance. Thromb Haemost 1995;74:345-51.
10. Ginsberg MH, Du X, O'Toole TE, Loftus JC. Platelet integrins. Thromb Haemost 1995;74:352-9.
11. Hawiger J. Mechanisms involved in platelet vessel wall interaction. Thromb Haemost 1995;74:369-72.
12. Lefkovits J, Topol EJ. Platelet glycoprotein IIb-IIIa receptor antagonists in coronary artery disease. Eur Heart J 1996;17:9-18.
13. Charo IF, Kieffer N, Phillips DR, et al. Platelet membrane glycoproteins. In: Colman RW, Hirsh J, Marder V, et al, eds. Hemostasis and thrombosis: basic principles and clinical practice. Philadelphia: JB Lippincott, 1994:489-507.
14. Wagner CL, Mascelli MA, Neblock DS, Weisman HF, Coller BS, Jordan RE. Analysis of GPIIb-IIIa receptor number by quantification of 7E3 binding to human platelets. Blood 1996;88:907-14.
15. Coller BS. A new murine monoclonal antibody reports an activation dependent change in the conformation and/or microenvironment of the glycoprotein IIb-IIIa complex. J Clin Invest 1985;76:101-8.
16. Coller BS, Anderson K, Weisman HF. New antiplatelet agents: platelet GPIIb-IIIa antagonists. Thromb Haemost 1995;74:302-8.
17. Faulds D, Sorkin EM. Abciximab (c7E3 Fab): a review of its pharmacology and therapeutic potential in ischaemic heart disease. Drugs 1994;48:583-98.
18. Tcheng JE. Dosing and administration of ReoPro™ (c7E3 Fab). J Invasive Cardiol 1994;6(suppl A):29A-33.
19. Yasuda T, Gold HK, Fallon JT, et al. Monoclonal antibody against the platelet glycoprotein (GP) IIb-IIIa receptor prevents coronary artery reocclusion after reperfusion with recombinant tissue-type plasminogen activator. J Clin Invest 1988;81:1284-91.
20. Gold HK, Coller BS, Yasuda T, et al. Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal anti-platelet GPIIb-IIIa antibody in a dog model. Circulation 1988;77:670-7.
21. Bhattacharya S, Jordan R, Machin S, et al. Blockade of the human platelet GPIIb-IIIa receptor by a murine monoclonal antibody fab fragment (7E3): potent dose-dependent inhibition of platelet function. Cardiovasc Drugs Ther 1995;9:665-75.
22. 2 fragments of murine monoclonal antibody 7E3 directed against human platelet glycoprotein IIb-IIIa in patients with unstable angina pectoris. J Clin Invest 1990;86:651-9.
23. Tcheng JE, Ellis SG, George BS, et al. Pharmacodynamics of chimeric glycoprotein IIb-IIIa integrin antiplatelet antibody fab 7E3 in high-risk coronary angioplasty. Circulation 1994;90:1757-64.
24. Bhattacharya S, Weisman HF, Morris KG, et al. Chimerization of monoclonal antibody 7E3 preserves the GPIIb-IIIa receptor blockade and platelet functional inhibition of murine 7E3 [abstr]. Clin Res 1991;39:196a.
25. Christopoulos C, Mackie L, Lahiri A, Machin S. Flow cytometric observations on the in vivo use of Fab fragments of a chimaeric monoclonal antibody to platelet glycoprotein IIb-IIIa. Blood Coagul Fibrinolysis 1993;4:729-37.
26. Tcheng JE, Kleinman NS, Miller MJ, Sane DC, Wang AL, Weisman HF. Chimeric antiplatelet GPIIb-IIIa receptor antibody (c-7E3) in elective PTCA: safety and platelet function inhibition [abstr]. Circulation 1991;84(suppl II):11-590.
27. Sweeny J, Holme S, Heaton A, et al. Infusion of a chimeric monoclonal Fab fragment (c7E3) against platelet glycoprotein IIb-IIIa potently inhibits platelet aggregation but does not affect in vivo platelet survival [abstr]. J Am Coll Cardiol 1993;21:253A.
28. Wagner CL, Knight D, McAleer MF, et al. Immunological comparison of murine and chimeric 7E3 Fab fragments in human clinical trials [abstr]. J Immunol 1993;150:158A.
29. Scarborough RM, Rose JW, Hsu MA, et al. Barbourin. J Biol Chem 1991;266:9359-62.
30. Verstraete M, Zoldhelyi P. Novel antithrombotic drugs in development. Drugs 1995,49:856-84.
31. Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb-IIIa receptors in cardiovascular medicine. N Engl J Med 1995;332:1553-9.
32. Ohman IM, Harrington RA, Lincoff AM, Kitt MM, Kleiman NS, Tcheng JE. Early clinical experience with integrelin, an inhibitor of the platelet glycoprotein IIb-IIIa integrin receptor. Eur Heart J 1995;16(suppl L):50-5.
33. Tcheng JE, Harrington RA, Dottke-Marchant K, et al. Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb-IIIa blocker integrelin in elective coronary intervention. Circulation 1995;91:2151-7.
34. Harrington RA, Kleiman NS, Kottke-Marchant K, et al. Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb-IIIa inhibitor during percutaneous coronary intervention. Am J Cardiol 1995;76:1222-7.
35. Charo IF, Scarborough RM, Du Mee CP, et al. Therapeutics. I. Pharmacodynamics of the GPIIb-IIIa antagonist integrelin: phase I clinical studies in normal healthy volunteers. Circulation 1992;86(suppl I):I-260.
36. Peerlinck K, De Lepeleire I, Goldberg M, et al. MK-383 (L-700,462), a selective nonpeptide platelet glycoprotein IIb-IIIa antagonist, is active in man. Circulation 1993;88:1512-17.
37. Kkereiakes DJ, Kleiman NS, Ambrose J, et al. Randomized, double-blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet IIb-IIIa blockade in high risk patients undergoing coronary angioplasty. J Am Coll Cardiol 1996;27:536-42.
38. Barren JS, Murphy G, Peerlinck K, et al. Pharmacokinetics and pharmacodynamics of MK-383, a selective non-peptide platelet glycoprotein-IIb-IIIa receptor antagonist, in healthy men. Clin Pharmacol Ther 1994;56:377-88.
39. Theroux P, Kouz S, Roy L, et al. Platelet membrane receptor glycoprotein IIb-IIIa antagonism in unstable angina. Circulation 1996;94:899-905.
40. Nicholson NS, Panzer-Knodle SG, Salyers AK, et al. SC-54684A: an orally active inhibitor of platelet aggregation. Circulation 1995;91:403-10.
41. Szalony JA, Haas NF, Salyers AK, et al. Extended inhibition of platelet aggregation with the orally active platelet inhibitor SC-54684A. Circulation 1995;91:411-16.
42. Simpfendorfer C, Kottke-Marchant K, Lowrie M, et al. First chronic platelet glycoprotein IIb-IIIa integrin blockade. Circulation 1997;96:76-81.
43. Kereiakes DJ, Runyon JP, Kleiman NS, et al. Differential dose-response to oral xemilofiban after antecedent intravenous abciximab. Circulation 1996;94:906-10.
44. Ellis SG, Tcheng JE, Navetta FI, et al. Safety and antiplatelet effect of murine monoclonal antibody 7E3 Fab directed against platelet glycoprotein IIb-IIIa in patients undergoing elective coronary angioplasty. Coron Artery Dis 1993;4:167-75.
45. The EPIC investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb-IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994;330:956-61.
46. Ryan TJ, Faxon DP, Gunnar RM, et al. Guidelines for percutaneous transluminal coronary angioplasty: a report of the American College of Cardiology/American Heart Association task force on assessment of diagnostic and therapeutic cardiovascular procedures (subcommittee on percutaneous transluminal coronary angioplasty). Circulation 1988;78: 486-502.
47. Rao AK, Pratt C, Berke A, et al. Thrombolysis in myocardial infarction (TIMI) trial - phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol 1988;11:1-11.
48. Topol EJ. Prevention of cardiovascular ischemic complications with new platelet glycoprotein IIb-IIIa inhibitors. Am Heart J 1995;130:666-72.
49. Topol EJ, Califf RM, Weisman HF, et al. Randomised trial of coronary intervention with antibody against platelet IIb-IIIa integrin for reduction of clinical restenosis: results at six months. Lancet 1994;343:881-6.
50. 3 blockade with percutaneous coronary intervention. JAMA 1997;278:450-84.
51. Reverter JC, Beguin S, Kessels H, Kumar R, Hemker HC, Coller BS. Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody: potential implications for the effect of c7E3 Fab treatment on acute thrombosis and "clinical restenosis." J Clin Invest 1996;98:863-74.
52. Lefkovits J, Blankenship JC, Anderson KM, et al. Increased risk of non-Q wave myocardial infarction after directional aterectomy is platelet dependent: evidence from the EPIC trial. J Am Coll Cardiol 1996;28:849-55.
53. Topol EJ, Leya F, Pinkerton CA, et al. A comparison of directional aterectomy with coronary angioplasty in patients with coronary artery disease. N Engl J Med 1993;329:221-7.
54. Holmes DR, Topol EJ, Califf RM, et al. A multicenter randomized trial of coronary angioplasty versus directional atherectomy for patients with saphenous vein bypass graft lesions. Circulation 1995;91:1966-74.
55. Aguirre FV, Topol EJ, Ferguson JJ, et al. Bleeding complications with the chimeric antibody to platelet glycoprotein IIb-IIIa integrin in patients undergoing percutaneous coronary intervention. Circulation 1995;91: 2882-90.
56. Boehrer JD, Kereiakes DJ, Navetta FI, Califf RM, Topol EJ. Effects of profound platelet inhibition with c7E3 before coronary angioplasty on complications of coronary bypass surgery. Am J Cardiol 1994;74:1166-70.
57. Popma JJ, Satler LF. Early and late clinical outcome after coronary angioplasty preformed with platelet glycoprotein IIb-IIIa receptor inhibition: the EPIC results. J Invasive Cardiol 1994;6(suppl A):19A-28.
58. Aguirre F. Post-procedural patient management: prevention and management of bleeding complications. J Invasive Cardiol 1994;6(suppl A):34A-7.
59. Brezina K, Murphy M, Stonner T. Care of the patient receiving ReoPro after angioplasty. J Invasive Cardiol 1994;6(suppl A):38A-42.
60. Lincoff AM, Tcheng JE, Califf RM, et al. Standard versus low-dose weight-adjusted heparin in patients treated with the platelet glycoprotein IIb-IIIa receptor antibody fragment abciximab (c7E3 Fab) during percutaneous coronary revascularization. Am J Cardiol 1997;79:286-91.
61. The EPILOG Investigators. Platelet glycoprotein IIb-IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N EnglJ Med 1997;336:1689-96.
62. The IMPACT-II Investigators. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Lancet 1997;349:1422-8.
63. Kleiman NS. Primary and secondary safety end points from IMPACT II. Am J Cardiol 1997;80(4A):29B-33.
64. 2+ on GP IIb-IIIa interactions with integrilin. Circulation 1997;96:1488-94.
65. The RESTORE Investigators. Effects of platelet glycoprotein IIb-IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 1997;96: 1445-53.
66. Kereiakes D, ed. Oral glycoprotein IIb/IIIa receptor blockade to inhibit thrombosis trial. Proceedings of the 70th scientific session of the American Heart Association, Orlando, FL, Nov 12, 1997.
67. Lincoff AM, Califf RM, Andersen KM, et al. Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb-IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization. J Am Coll Cardiol 1997;30:149-56.
68. The CAPTURE Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet 1997;349:1429-35.
69. Simoons ML, Jan de Boer J, van den Brand MJ, et al. Randomized trial of a GPIIb-IIIa platelet receptor blocker in refractory unstable angina. Circulation 1994;89:596-603.
70. Schulman SP, Goldschmidt-Clermont PJ, Topol EJ, et al. Effects of integrelin, a platelet glycoprotein IIb-IIIa receptor antagonist, in unstable angina. Circulation 1996;94:2083-9.
71. Lincoff RA, Harrington RM, Califf RM, eds. Platelet IIb-IIIa in unstable angina: receptor suppression using integrilin therapy. Proceedings of the 19th congress of the European Society of Cardiology, Stockholm, Sweden, Aug 25, 1997.
72. Peiper J, Gibson GA, Johnson KA, eds. GP IIb-IIIa inhibition: evolution of drug therapy in acute coronary syndromes. Proceedings of the midyear clinical meeting of the America Society for Hospital Pharmacists, Atlanta, GA, Dec 9, 1997.
73. White H, Theroux P, eds. Platelet receptor inhibition for ischemic syndrome management (PRISM and PRISM-PLUS). Proceedings of the American College of Cardiology 46th annual scientific meeting, Anaheim, CA, March 16-19, 1997.
74. Lincoff AM., ed. Prospects for platelet GPIIb-IIIa inhibition in acute myocardial infarction. Proceedings of the American College of Cardiology Cleveland Clinic synopsis of myocardial reperfusion, Cleveland, OH, March 18, 1995.
75. Kleiman NS, Ohman EM, Califf RM, et al. Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy. Results of the thrombolysis and angioplasty in myocardial infarction (TAMI) 8 pilot study. J Am Coll Cardiol 1993;22:381-9.
76. Lefkovits J, Ivanhoe RJ, Califf RM, et al. Effects of platelet glycoprotein IIb-IIIa receptor blockade by a chimeric monoclonal antibody (abciximab) on acute and six-month outcomes after percutaneous transluminal coronary angioplasty for acute myocardial infarction. Am J Cardiol 1996;77: 1045-51.
77. Brener SJ, Barr ED, Hohen HJ, et al. Abciximab reduces urgent target vessel revascularization at 30 days after primary angioplasty, independently of acute angiographic results. The RAPPORT trial [abstr]. Circulation 1997; 96(suppl I):I-473.
78. Ohman EM, Kleiman NS, Gacioch G, et al. Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb-IIIa integrin receptor blockade with integrilin in acute myocardial infarction. Results of a randomized, placebo-controlled, dose-ranging trial. Circulation 1997;95: 846-54.
79. Serruys PW, De Jaegere P, Kiemeneij F, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med 1994;331:489-95.
80. Fischman KL, Leon MB, Bairn DS, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med 1994;331:496-501.
81. Versaci F, Gaspardone A, Phil M, et al. A comparison of coronary-artery stenting with angioplasty for isolated stenosis of the proximal left anterior descending coronary artery. N Engl J Med 1997;336:817-22.
82. Neumann FJ, Gawaz M, Ott I, May A, Mossmer G, Schomig A. Prospective evaluation of hemostatic predictors of subacute stent thrombosis after coronary Palmaz-Schatz stenting. J Am Coll Cardiol 1996;27:15-21.
83. Makkar RR, Litvack F, Eigler NL, et al. Effects of GP IIb-IIIa receptor monoclonal antibody (7E3), heparin, and aspirin in an ex vivo canine arteriovenous shunt model of stent thrombosis. Circulation 1997;95:1015-21.
84. Kereiakes DJ, Lincoff ML, Simoons MJ, et al. Complementarity of stenting and abciximab for percutaneous coronary intervention [abstr]. J Am Coll Cardiol 1998;31(suppl A):54A.
85. Zidar JP, Kruse KR, Thel MC, et al. Integrelin for emergency coronary artery stenting. J Am Coll Cardiol 1996;27:138A.
86. Kereiakes DJ, Kleiman N, Ferguson JJ, et al. Sustained platelet glycoprotein IIb-IIIa blockade with oral xemilofiban in 170 patients after coronary stent deployment. Circulation 1997;96:1117-21.
87. Mark DB, Talley JD, Topol EJ, et al. Economic assessment of platelet glycoprotein IIb-IIIa inhibition for prevention of ischemic complications of high-risk coronary angioplasty. Circulation 1996;94:629-35.
88. Hillegass WB. The economics of IIb-IIIa therapy. J Invasive Cardiol 1996;8(suppl B):30B-3.
89. Holmes DR, Bell MR, Rihal CS. Is routine ReoPro use needed for higher risk coronary stenting? [abstr]. Circulation 1997;96(suppl I):I-654.
90. Winslow R. Centocor drug gets a boost from major study. The Wall Street Journal, 31 Mar 1998, sec. B-6.
91. Narins CR, Ellis SG, Hammel JP. Does abciximab improve outcome after angioplasty in diabetics? Long term follow-up results from the EPIC study [abstr]. Circulation 1997;96(suppl I):I-162.